PKI Chart

1 Month

	Date	Diff
	2023-06-28	+0.64 %
The article discusses the positive growth projections for the PET Scanners Market, which is expected to drive up the stock of PerkinElmer (PKI) as a key market player in the PET scanners industry. The growth is attributed to factors such as the increasing demand for PET analysis in radiopharmaceuticals, advancements in technology, and the integration of X-ray tomography with PET. Increased funding for healthcare facilities and the rising incidence of diseases like cancer and cardiovascular diseases also contribute to the market's growth.
	2023-04-25	-5.44 %
PerkinElmer's (PKI) stock went down by 5.44% following news of the company declaring a regular quarterly dividend of $0.07 per share of common stock payable on August 11, 2023 to all shareholders of record at the close of business on July 21, 2023.
	2023-04-24	+1.44 %
Perkinelmer (PKI) stock went up 1.44% after an article in Nature Biotechnology reported that language models can efficiently evolve human antibodies, suggesting that learning from natural evolutionary strategies could guide artificial evolution.
	2023-04-19	+1.06 %
Perkinelmer (PKI) stock went up last night, possibly due to a new study that found a polyoxometalate (POM) cluster that enables the nanoscale ultrafiltration-based separation of americium from lanthanides in used nuclear fuel, addressing a long-standing challenge in the nuclear industry, according to a Nature article.
	2023-04-18	-1.34 %
Semtech Corporation announces new appointments to its Board of Directors and nominating and governance committee which are expected to contribute to its growth, but it remains unclear why PerkinElmer’s stock went down on the same day.
	2023-04-13	+1.96 %
Perkinelmer (PKI) stock went up by 1.96% after an article was published on a new biomaterial-based approach to prepare highly active extracellular vesicles from endothelial progenitor cells (EPCs) by stimulating them with silicate ions derived from bioactive silicate ceramics, which can be effective in the treatment of myocardial infarction by significantly enhancing angiogenesis.
	2023-04-12	+0.11 %
PerkinElmer Inc. will release its first quarter 2023 financial results on May 11, 2023, and the stock was up 0.11%; the reason for the stock going up is not stated in the article.
	2023-04-10	-0.52 %
PerkinElmer (PKI) stock went down by 0.52% as PerkinElmer appears to be overvalued by 27%, based on discounted cash flow valuation, and its stock price is currently priced at $134 compared to an intrinsic value of $105.20.
	2023-04-05	+1.11 %
PerkinElmer Inc. (NYSE: PKI) stock went up by 1.11% following the release of Renaissance Large Cap Growth Strategy's Q4 2022 investor letter, which highlighted PKI as one of its stocks.
	2023-04-03	-1.42 %
The stock of PerkinElmer (PKI) went down by 1.42% due to the formation of a strategic advisory board by Legend Biotech Corporation and the appointment of Michel Vounatsos and John Maraganore, former CEOs of Biogen Inc. and Alnylam Pharmaceuticals, respectively, as advisors to advise the company on strategic initiatives to advance its cell therapy platforms.
	2023-03-31	+1.73 %
PerkinElmer Inc. stock rose 1.73%, reaching $133.26, and posted its seventh consecutive day of gains, with no clear reason for the increase provided in the article.
	2023-03-24	+1.98 %
PerkinElmer (PKI) stock went up 1.98% after the company developed TriSb92, a highly potent and manufacturable trimeric antibody-mimetic sherpabody that neutralizes SARS-CoV-2, including the latest Omicron variants, and could be used as a nasal spray for protecting susceptible individuals from COVID-19.
	2023-03-15	-0.63 %
This article is about the development of JNJ-1802, a first-in-class antiviral agent against dengue, which has successfully completed a phase I first-in-human clinical study and is now progressing in clinical studies for the prevention and treatment of dengue; this news is not related to the recent -0.63% drop in the PerkinElmer (PKI) stock.
	2023-03-10	-2.65 %
The article is not about PerkinElmer (PKI) stock going down, but rather about Bionano Genomics' fourth-quarter and full-year 2022 financial results, which were positive and showed growth in their installed base of Saphyr systems and flowcell sales, among other achievements.
	2023-03-08	-0.5 %
PerkinElmer (PKI) stock went down by 0.5% because of the lack of a defined structure of the third intracellular loop (ICL3) in G protein-coupled receptors (GPCRs) and its high sequence divergence among GPCRs, which complicates the characterization of its involvement in receptor signalling, though the study found that ICL3 autoregulates receptor activity through a dynamic conformational equilibrium between states that block or expose the receptor’s G protein-binding site.
	2023-03-07	-2.87 %
The article is not about PerkinElmer (PKI) stock; it is a scientific report about the use of a fluorescent probe, gGlu-HMRG, for intraoperative visualization of thymomas and thymic carcinomas. Therefore, the article does not provide any explanation as to why PKI stock may have gone down.
	2023-02-28	+1.1 %
PerkinElmer Inc. stocks go up because they are related to the medical industry which is doing well.
	2023-02-24	-2.25 %
The article discusses the upcoming release of the EnVision Nexus system, which is designed for high-throughput screening (HTS) applications. The system isfast, sensitive, and integrates well with other PerkinElmer products. This is good news for researchers who need a fast and sensitive system to screen millions of samples. However, some analysts believe that the system is too expensive and may not be able to compete with other HTS platforms on the market. This could lead to lower stock prices for perkinelmer.
	2023-02-22	+0.42 %
The stock of perkinelmer(PKI) goes up because they announced that they will be presenting at the Cowen 43rd Annual Health Care Conference and the Barclays Global Healthcare Conference.
	2023-01-26	-0.09 %
PerkinElmer's dividend is being cut, likely signaling a tougher future for the company.